Lipid raft disarrangement as a result of neuropathological progresses: A novel strategy for early diagnosis?

Neuroscience

Volumn 245, Issue , 2013, Pages 26-39

  Marin, R ^a   Rojo, J A ^b   Fabelo, N ^a   Fernandez, C E ^a   Diaz, M ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

Alzheimer's disease; Early neuropathological biomarkers; Lipid rafts; Parkinson's disease; Signalosomes

Indexed keywords

ALPHA SECRETASE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BETA SECRETASE; BIOLOGICAL MARKER; GAMMA SECRETASE;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; LIPID COMPOSITION; LIPID RAFT; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; MEMBRANE MICRODOMAINS; NERVOUS SYSTEM DISEASES;

EID: 84877881574     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.04.025     Document Type: Review

References (170)

1. Abad Rodriguez J., Ledesma M.D., Craessaerts K., Perga S., Medina M., Delacourte A., Dingwall C., De Strooper B., Dotti C.G. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 2004, 167:953-960.
2. Albert M.S. Changes in cognition. Neurobiol Aging 2011, 32(Suppl. 1):S58-S63.
3. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):270-279.
4. Aisen P.S. Clinical trial methodologies for disease-modifying therapeutic approaches. Neurobiol Aging 2011, 32(Suppl. 1):S64-S66.
5. Association Alzheimer.'s. Alzheimer's disease facts and figures. Alzheimers Dement 2011, 7:208-244.
6. Ariga T., McDonald M.P., Yu R.K. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease - a review. J Lipid Res 2008, 49(6):1157-1175.
7. Assayag K., Yakunin E., Loeb V., Selkoe D.J., Sharon R. Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. Am J Pathol 2007, 171(6):2000-2011.
8. Bar-On P., Crews L., Koob A.O., Mizuno H., Adame A., Spencer B., Masliah E. Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem 2008, 105(5):1656-1667.
9. Barceló-Coblijn G., Golovko M.Y., Weinhofer I., Berger J., Murphy E.J. Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. J Neurochem 2007, 101(1):132-141.
10. Bates K.A., Verdile G., Li Q.X., Ames D., Hudson P., Masters C.L., Martins R.N. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 2009, 14(5):469-486.
11. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005, 58(4):495-505.
12. Ben Gedalya T., Loeb V., Israeli E., Altschuler Y., Selkoe D.J., Sharon R. Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic 2009, 10(2):218-234.
13. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
14. Bjorkhem I., Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004, 24:806-815.
15. Borroni B., Aqosti C., Marcello E., Di Luca M., Padovani A. Blood cell markers in Alzheimer Disease: amyloid precursor protein form ratio in platelets. Exp Gerontol 2010, 45:53-56.
16. Breen D.P., Michell A.W., Barker R.A. Parkinson's disease - the continuing search for biomarkers. Clin Chem Lab Med 2011, 49:393-401.
17. Bucciantini M., Nosi D., Forzan M., Russo E., Calamai M., Pieri L., Formigli L., Quercioli F., Soria S., Pavone F., Savistchenko J., Melki R., Stefani M. Toxic effects of amyloid fibrils on cell membranes: the importance of ganglioside GM1. FASEB J 2012, 26(2):818-831.
18. Cappai R., Barnham K.J. Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. Neurochem Res 2008, 33(3):526-532.
19. Chadwick W., Brenneman R., Martin B., Maudsley S. Complex and multidimensional lipid raft alterations in a murine model of Alzheimer's disease. Int J Alzheimers Dis 2010, 2010:604-792.
20. Chaudhuri K.R., Martinez-Martin P. Quantitation of non-motor symptoms in Parkinson's disease. Eur J Neurol 2008, 15(Suppl. 2):2-7.
21. Chahine L.M., Stern M.B. Diagnostic markers for Parkinson's disease. Curr Opin Neurol 2011, 24(4):309-317.
22. Chan R.B., Oliveira T.G., Cortes E.P., Honig L.S., Duff K.E., Small S.A., Wenk M.R., Shui G., Di Paolo G. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 2012, 287(4):2678-2688.
23. Chen M., Inestrosa N.C., Ross G.S., Fernandez H.L. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 1995, 213:96-103.
24. Chen T.Y., Liu P.H., Ruan C.T., Chiu L., Kung F.L. The intracellular domain of amyloid precursor protein interacts with flotillin-1, a lipid raft protein. Biochem Biophys Res Commun 2006, 342(1):266-272.
25. Cho D.H., Nakamura T., Fang J., Cieplak P., Godzik A., Gu Z., Lipton S.A. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 2009, 324(5923):102-105.
26. Chung K.K., Thomas B., Li X., Pletnikova O., Troncoso J.C., Marsh L., Dawson V.L., Dawson T.M. S-nitrosylation of parkin regulates ubiquitination and compromises Parkin's protective function. Science 2004, 304(5675):1328-1331.
27. Chung H.Y., Cesari M., Anton S., Marzetti E., Giovannini S., Seo A.Y., Carter C., Yu B.P., Leeuwenburgh C. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev 2009, 8(1):18-30.
28. Colciaghi F., Marcello E., Borroni B., Zimmermann M., Caltaqirone C., Cattabeni C., Cattabeni F., Padovani A., Di Luca M., Platelet A.P.P. ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 2004, 62:498-501.
29. Cole N.B., Murphy D.D., Grider T., Rueter S., Brasaemle D., Nussbaum R.L.J. Biol Chem 2002, 277:6344-6352.
30. Cummings J.L. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement 2011, 7(3):e13-e44.
31. Dalfó E., Portero-Otín M., Ayala V., Martínez A., Pamplona R., Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 2005, 64(9):816-830.
32. Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 1998, 273(16):9443-9449.
33. Del Tredici K., Rüb U., De Vos R.A., Bohl J.R., Braak H. Where does Parkinson disease pathology begin in the brain?. J Neuropathol Exp Neurol 2002, 61(5):413-426.
34. Diaz M.L., Fabelo N., Marin R. Genotype-induced changes in biophysical properties of frontal cortex lipid raft from APP/PS1 transgenic mice. Front Physiol 2012, 3:454-459.
35. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., Tanner C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
36. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6(8):734-746.
37. Ehehalt R., Keller P., Haass C., Thiele C., Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003, 160:113-123.
38. Eriksen J.L., Wszolek Z., Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005, 62(3):353-357.
39. Evin G., Zhu A., Holsinger R.M., Masters C.L., Li Q.X. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. J Neurosci Res 2003, 74(3):386-392.
40. Fabelo N., Martín V., Santpere G., Marín R., Torrent L., Ferrer I., Díaz M. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol Med 2011, 17(9-10):1107-1118.
41. Fabelo N., Martín V., Marin R., Santpere G., Aso E., Ferrer I., Diaz M. Evidence for premature "Lipid raft aging" in APP/PS1 double transgenic mice, a familial model of Alzheimer's disease. J Neuroendocrinol Exp Neurol 2012, 71(10):868-881.
42. Ferrer I. Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects. Prog Neurobiol 2009, 88(2):89-103.
43. Ferrer I. Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. J Bioenerg Biomembr 2009, 41(5):425-431.
44. Ferrer I., Martinez A., Blanco R., Dalfó E., Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm 2011, 118(5):821-839.
45. Fleck D., Garratt A.N., Haass C., Willem M. BACE1 dependent neuregulin processing: review. Curr Alzheimer Res 2012, 9(2):178-183.
46. Forlenza O.V., Diniz B.S., Gattaz W.F. Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med 2010, 8:89.
47. Fortin D.L., Troyer M.D., Nakamura K., Kubo S., Anthony M.D., Edwards R.H. Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 2004, 24(30):6715-6723.
48. Galimberti D., Scarpini E. Progress in Alzheimer's disease. J Neurol 2012, 259(2):201-211.
49. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001, 2(7):492-501.
50. Golovko M.Y., Faergeman N.J., Cole N.B., Castagnet P.I., Nussbaum R.L., Murphy E.J. Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding. Biochemistry 2005, 44:8251-8259.
51. Gellermann G.P., Appel T.R., Tannert A., Radestock A., Hortschansky P., Schroeckh V., Leisner C., Lütkepohl T., Shtrasburg S., Röcken C., Pras M., Linke R.P., Diekmann S., Fändrich M. Raft lipids as common components of human extracellular amyloid fibrils. Proc Natl Acad Sci 2005, 102:6297-6302.
52. Galasko D., Montine T.J. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med 2010, 4(1):27-36.
53. Grimm M.O., Rothhaar T.L., Hartmann T. The role of APP proteolytic processing in lipid metabolism. Exp Brain Res 2012, 217(3-4):365-375.
54. Grimm M.O., Kuchenbecker J., Grösgen S., Burg V.K., Hundsdörfer B., Rothhaar T.L., Friess P., de Wilde M.C., Broersen L.M., Penke B., Péter M., Vígh L., Grimm H.S., Hartmann T. Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J Biol Chem 2011, 286(16):14028-14039.
55. Ghidoni R., Benussi L., Paterlini A., Albertini V., Binetti G., Emanuele E. Cerebrospinal fluid biomarkers for Alzheimer's disease: the present and the future. Neurodegener Dis 2011, 8(6):413-420.
56. Guirland C., Zheng J.Q. Membrane lipid rafts and their role in axon guidance. Adv Exp Med Biol 2007, 621:144-155.
57. Grösgen S., Grimm M.O., Friess P., Hartmann T. Role of amyloid beta in lipid homeostasis. Biochim Biophys Acta 2010, 1801(8):966-974.
58. Halford R.W., Russell D.W. Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan. Proc Natl Acad Sci U S A 2009, 106(9):3502-3506.
59. Han X. Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2005, 2:65-77.
60. Harris B., Pereira I., Parkin E. Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein. Brain Res 2009, 1296:203-215.
61. Hayashi H., Kimura N., Yamaguchi H., Hasegawa K., Yokoseki T., Shibata M., Yamamoto N., Michikawa M., Yoshikawa Y., Terao K., Matsuzaki K., Lemere C.A., Selkoe D.J., Naiki H., Yanagisawa K. A seed for Alzheimer amyloid in the brain. J Neurosci 2004, 24(20):4894-4902.
62. Herrera J.L., Díaz M., Hernández-Fernaud J.R., Salido E., Alonso R., Fernández C., Morales A., Marin R. Voltage-dependent anion channel as a resident protein of lipid rafts: pots-transductional regulation by estrogens and involvement in neuronal preservation against Alzheimer's disease. J Neurochem 2011, 116:820-827.
63. Hicks D.A., John D., Makova N.Z., Henderson Z., Nalivaeva N.N., Turner A.J. Membrane targeting, shedding and protein interactions of brain acetylcholinesterase. J Neurochem 2011, 116(5):742-746.
64. Hicks D.A., Nalivaeva N.N., Turner A. Lipid rafts and Alzheimer's disease: protein-lipid interactions and perturbation of signaling. Front Physiol 2012, 3(189):1-18.
65. Holtzman D.M., Morris J.C., Goate A.M. Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011, 3(77):77sr1.
66. Hur J.Y., Teranishi Y., Kihara T., Yamamoto N.G., Inoue M., Hosia W., Hashimoto M., Winblad B., Frykman S., Tjernberg L.O. Identification of novel γ-secretase-associated proteins in detergent-resistant membranes from brain. J Biol Chem 2012, 287(15):11991-12005.
67. Ihara M., Yamasaki N., Hagiwara A., Tanigaki A., Kitano A., Hikawa R., Tomimoto H., Noda M., Takanashi M., Mori H., Hattori N., Miyakawa T., Kinoshita M. Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron 2007, 53:519-533.
68. Ikezu T., Trapp B.D., Song K.S., Schlegel A., Lisanti M.P., Okamoto T. Caveolae, plasma membrane microdomains for processing of the Alpha secretase mediated amyloid precursor protein. J Biol Chem 1998, 273:10485-10495.
69. Iwatsubo T. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease. J Neurol 2003, 250(Suppl. 3):III11-III14.
70. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9(1):119-128.
71. Janvin C.C., Larsen J.P., Aarsland D., Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006, 21(9):1343-1349.
72. Jicha G.A., Markesbery W.R. Omega-3 fatty acids: potential role in the management of early Alzheimer's disease. Clin Interv Aging 2010, 5:45-61.
73. Kaether C., Haass C. A lipid boundary separates APP and secretases and limits amyloid beta-peptide generation. J Cell Biol 2004, 167(5):809-812.
74. Kakio A., Nishimoto S., Kozutsumi Y., Matsuzaki K. Formation of a membrane-active form of amyloid beta-protein in raft-like model membranes. Biochem Biophys Res Commun 2003, 303(2):514-518.
75. Kalvodova L., Kahya N., Schwille P., Ehehalt R., Verkade P., Drechsel D., Simons K. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 2005, 280:36815-36823.
76. Kapoor A., Hsu W.M., Wang B.J., Wu G.H., Lin T.Y., Lee S.J., Yen C.T., Liang S.M., Liao Y.F. Caveolin-1 regulates γ-secretase-mediated AβPP processing by modulating spatial distribution of γ-secretase in membrane. J Alzheimers Dis 2010, 22(2):423-442.
77. Kwak Y.D., Wang R., Li J.J., Zhang Y.W., Xu H., Liao F.F. Differential regulation of BACE1 expression by oxidative and nitrosative signals. Mol Neurodegener 2011, 6:17.
78. Kubo S., Nemani V.M., Chalkley R.J., Anthony M.D., Hattori N., Mizuno Y., Edwards R.H., Fortin D.L. A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem 2005, 280(36):31664-31672.
79. Lai A.Y., McLaurin J. Mechanisms of amyloid-beta peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins. Int J Alzheimers Dis 2010, 2011:548380.
80. Lajoie P., Goetz J.G., Dennis J.W., Nabi I.R. Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biol 2009, 185:381-385.
81. Lane R.M., Farlow M.R. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. J Lipid Res 2005, 46(5):949-968.
82. Lee S.J., Liyanage U., Bickel P.E., Xia W., Lansbury P.T., Kosik K.S. A detergent-insoluble membrane compartment contains Abeta in vivo. Nat Med 1998, 4(6):730-734.
83. Lee H., Woodman S.E., Engelman J.A., Volonte D., Galbiati F., Kaufman H.L., Lublin D.M., Lisanti M.P. Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase. J Biol Chem 2001, 276:35150-35158.
84. Lemkul J.A., Bevan D.R. Lipid composition influences the release of Alzheimer's amyloid β-peptide from membranes. Protein Sci 2011, 20(9):1530-1545.
85. Licker V., Kovari E., Hochstrasser D.F., Burkhard P.R. Proteomics in human Parkinson's disease research. J Proteomics 2009, 73:10-29.
86. Lingwood D., Simons K. Lipid rafts as a membrane organizing principle. Science 2010, 327:46-50.
87. Lisanti M.P., Scherer P.E., Tang Z., Sargiacomo M. Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis. Trends Cell Biol 1994, 4:231-235.
88. Lutjohann D., Papassotiropoulos A., Bjorkhem I., Locatelli S., Bagli M., Oehring R.D., Schlegel U., Jessen F., Rao M.L., von Bergmann K., Heun R. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 2000, 41:195-198.
89. Lutjohann D. Cholesterol metabolism in the brain: importance of 24S-hydroxylation. Acta Neurol Scand Suppl 2006, 185:33-42.
90. Ma D.W. Lipid mediators in membrane rafts are important determinants of human health and disease. Appl Physiol Nutr Metab 2007, 32(3):341-350.
91. Madeira A., Yang J., Zhang X., Vikeved E., Nilsson A., Andrén P.E., Svenningsson P. Caveolin-1 interacts with alpha-synuclein and mediates toxic actions of cellular alpha-synuclein overexpression. Neurochem Int 2011, 59(2):280-289.
92. Mangialasche F., Polidori M.C., Monastero R., Ercolani S., Camarda C., Cecchetti R., Mecocci P. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res Rev 2009, 8(4):285-305.
93. Mariani E., Polidori M.C., Cherubini A., Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 827(1):65-75.
94. Marin R., Ramírez C.M., González M., González-Muñoz E., Zorzano A., Camps M., Alonso R., Díaz M. Voltage-dependent anion channel (VDAC) participates in amyloid beta-induced toxicity and interacts with plasma membrane estrogen receptor α in septal and hippocampal neurons. Mol Membr Biol 2007, 24:148-160.
95. Marin R., Ramirez C.M., Morales A., Gonzalez M., Alonso R., Diaz M. Modulation of Aβ-induced neurotoxicity by estrogen receptor alpha and other associated proteins in lipid rafts. Steroids 2008, 73:992-996.
96. Marin R., Diaz M., Alonso R., Sanz A., Arevalo M.A., Garcia-Segura L.M. Role of estrogen receptor in membrana-initiated signaling in neural cells: interaction with IGF-1 receptor. J Steroid Biochem Mol Biol 2009, 114:2-7.
97. Marin R. Signalosomes in the brain: relevance in the development of certain neuropathologies such as Alzheimer's disease. Front Physiol 2011, 2(23):1-3.
98. Marino M., Ascenzi P., Acconcia F. S-palmitoylation modulates estrogen receptor alpha localization and functions. Steroids 2006, 71:298-303.
99. Martín V., Fabelo N., Santpere G., Puig B., Marín R., Ferrer I., Díaz M. Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis 2010, 19(2):489-502.
100. Martinez Z., Zhu M., Han S., Fink A.L. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 2007, 46(7):1868-1877.
101. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
102. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):263-269.
103. Metzler-Baddeley C. A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer's disease and Parkinson's disease with dementia. Cortex 2007, 43(5):583-600.
104. Michel V., Bakovic M. Lipid rafts in health and disease. Biol Cell 2007, 99:129-140.
105. Milne G.L., Sanchez S.C., Musiek E.S., Morrow J.D. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protocol 2007, 2:221-226.
106. Molander-Melin M., Blennow K., Bogdanovic N., Dellheden B., Månsson J.E., Fredman P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem 2005, 92(1):171-182.
107. Mollenhauer B., Locascio J.J., Schulz-Schaeffer W., Sixel-Doring F., Trenkwalder C., Schlossmacher M.G. Alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with Parkinsonism: a cohort study. Lancet Neurol 2011, 10:230-240.
108. Mollenhauer B., Zhang J. Biochemical premotor biomarkers for Parkinson's disease. Mov Disord 2012, 27(5):644-650.
109. Montine T.J., Neely M.D., Quinn J.F., Beal M.F., Markesbery W.R., Roberts L.J., Morrow J.D. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med 2002, 33:620-626.
110. Montine T.J., Montine K.S., McMahan W., Markesbery W.R., Quinn J.F., Morrow J.D. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 2005, 7(1-2):269-275.
111. Morrow I.C., Rea S., Martin S., Prior I.A., Prohaska B., Hancock J.F., James D.E., Parton R.G. Flotillin-1/Reggie-2 traffics to surface raft domains via a novel Golgi-independent pathway. J Biol Chem 2002, 277:48834-48841.
112. Mufson E.J., Binder L., Counts S.E., DeKosky S.T., de Toledo-Morrell L., Ginsberg S.D., Ikonomovic M.D., Perez S.E., Scheff S.W. Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol 2012, 123(1):13-30.
113. Murakami Y., Siripanyapinyo U., Hong Y., Kang J.Y., Ishihara S., Nakakuma H., Yusuke M., Kinoshita T. PIG-W is critical for inositol acylation but not for flipping of glycosylphosphatidylinositol-anchor. Mol Biol Cell 2003, 14:4285-4295.
114. Oliveira T.G., Di Paolo G. Phospholipase D in brain function and Alzheimer's disease. Biochim Biophys Acta 2010, 1801(8):799-805.
115. Ostrom R.S., Bundey R.A., Insel P.A. Nitric oxide inhibition of adenylyl cyclase type 6 activity is dependent upon lipid rafts and caveolin signaling complexes. J Biol Chem 2004, 279(19):19846-19853.
116. Ortega R.M., Rodríguez-Rodríguez E., López-Sobaler A.M. Effects of omega 3 fatty acids supplementation in behavior and non-neurodegenerative neuropsychiatric disorders. Br J Nutr 2012, 107(Suppl. 2):S261-S270.
117. Pacheco C., Aguayo L.G., Opazo C. An extracellular mechanism that can explain the neurotoxic effects of α-synuclein aggregates in the brain. Front Physiol 2012, 3(297):1-10.
118. Pahwa R., Lyons K.E. Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines. Am J Manag Care 2010, 16(Suppl. Implications):S94-S99.
119. Paris L., Cecchetti S., Spadaro F., Abalsamo L., Lugini L., Pisanu M.E., Iorio E., Natali P.G., Ramoni C., Podo F. Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res 2010, 12(3):R27.
120. Parkkinen L., Kauppinen T., Pirttilä T., Autere J.M., Alafuzoff I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005, 57(1):82-91.
121. Parton R.G. Caveolae-form ultrastructure to molecular mechanisms. Nat Rev Mol Cell Biol 2003, 4:162-167.
122. Pedram A., Razandi M., Sainson R.C., Kim J.K., Hughes C.C., Levin E.R. A conservedmechanism for steroid receptor translocation to the plasma membrane. J Biol Chem 2007, 282:22278-22288.
123. Perrin R.J., Woods W.S., Clayton D.F., George J.M. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J Biol Chem 2001, 276(45):41958-41962.
124. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004, 256:183-194.
125. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., Winblad B. Current concepts in mild cognitive impairment. Arch Neurol 2001, 58(12):1985-1992.
126. Poletti M., Emre M., Bonuccelli U. Mild cognitive impairment and cognitive reserve in Parkinson's disease. Parkinsonism Relat Disord 2011, 17(8):579-586.
127. Poon H.F., Calabrese V., Scapagnini G., Butterfield D.A. Free radicals and brain aging. Clin Geriatr Med 2004, 20(2):329-359.
128. Pratico D., Sung S. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J Alzheimers Dis 2004, 6:171-175.
129. Ramirez C.M., Gonzalez M., Diaz M., Alonso R., Ferrer I., Santpere G., Puig B., Meyer G., Marin R. VDAC and ERα interaction in caveolae from human cortex is altered in Alzheimer s disease. Mol Cell Neurosci 2009, 42:172-183.
130. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007, 13(11):1359-1362.
131. Riddell D.R., Christie G., Hussain I., Dingwall C. Compartmentalization of beta-secretase(Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr Biol 2001, 11(16):1288-1293.
132. Ross G.W., Abbott R.D., Petrovitch H., Tanner C.M., Davis D.G., Nelson J., Markesbery W.R., Hardman J., Masaki K., Launer L., White L.R. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 2006, 21(12):2062-2067.
133. Rushworth J.V., Hooper N.M. Lipid rafts: linking Alzheimer's amyloid-β production, aggregation and toxicity at neuronal membranes. Int J Alzheimers Dis 2010, 2011:603052.
134. Sakurai T., Kaneko K., Okuno M., Wada K., Kashiyama T., Shimizu H., Akagi T., Hashikawa T., Nukina N. Membrane microdomain switching: a regulatory mechanism of amyloidprecursor protein processing. J Cell Biol 2008, 183(2):339-352.
135. Samgard K., Zetterberg H., Blennow K., Hansson O., Minthon L., Londos E. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int J Geriatr Psychiatry 2010, 25(4):403-410.
136. Sato I., Obata Y., Kasahara K., Nakayama Y., Fukumoto Y., Yamasaki T., Yokohama K.K., Saito T., Yamaguchi N. Differential trafficking of Src, Lyn, Yes and Fyn is specified by the state of palmitoylation in the SH4 domain. J Cell Sci 2009, 122(Pt. 7):965-975.
137. Schneider A., Rajendran L., Honsho M., Gralle M., Donnert G., Wouters F., Hell S.W., Simons M. Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J Neurosci 2008, 28(11):2874-2882.
138. Schengrund C.L. Lipid rafts: keys to neurodegeneration. Brain Res Bull 2010, 82(1-2):7-17.
139. Sierks M.R., Chatterjee G., McGraw C., Kasturirangan S., Schulz P., Prasad S. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb) 2011, 3(12):1188-1196.
140. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., Simons K. Cholesterol depletion inhibits the generation of beta amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998, 95:6460-6464.
141. Simmons B.B., Hartmann B., Dejoseph D. Evaluation of suspected dementia. Am Fam Physician 2011, 84(8):895-902.
142. Simonsen A.H., Hagnelius N.O., Waldemar G., Nilsson T.K., McGuire J. Protein markers for the differential diagnosis of vascular dementia and Alzheimer's disease. Int J Proteomics 2012, 2012:824024.
143. Sharon R., Bar-Joseph I., Frosch M.P., Walsh D.M., Hamilton J.A., Selkoe D.J. Altered fatty acid composition of dopaminergic neurons expressing α-synuclein and human brains with α-synucleinopathies. Neuron 2003, 37(583):595.
144. Shearer J., Green C., Ritchie C.W., Zajicek J.P. Health state values for use in the economic evaluation of treatments for Alzheimer's disease. Drugs Aging 2012, 29(1):31-43.
145. Shi C., Liu J., Wu F., Zhu X., Yew D.T., Xu J. β-Sitosterol inhibits high cholesterol-induced platelet β-amyloid release. J Bioenerg Biomembr 2011, 43(6):691-697.
146. Sidhu A., Wersinger C., Vernier P. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?. FASEB J 2004, 18:637-647.
147. Stefanacci R.G. The costs of Alzheimer's disease and the value of effective therapies. Am J Manag Care 2011, 17(Suppl. 13):S356-S362.
148. Swerdlow R.H. Brain aging, Alzheimer's disease, and mitochondria. Biochim Biophys Acta 2011, 1812(12):1630-1639.
149. Thinnes F.P. Alzheimer disease controls cancer - concerning the apoptogenic interaction of cell membrane-standing type-1 VDAC and amyloid peptides via GxxxG motifs. Mol Genet Metab 2012, 106(4):502-503.
150. Tsui-Pierchala B.A., Encinas M., Milbrandt J., Johnson E.M. Lipid rafts in neuronal signaling and function. Trends Neurosci 2002, 25:412-417.
151. Uehara T., Nakamura T., Yao D., Shi Z.Q., Gu Z., Ma Y., Masliah E., Nomura Y., Lipton S.A. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006, 441(7092):513-517.
152. van Dijk K.D., Teunissen C.E., Drukarch B., Jimenez C.R., Groenewegen H.J., Berendse H.W., van de Berg W.D. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis 2010, 39(3):229-241.
153. Vetrivel K.S., Thinakaran G. Membrane rafts in Alzheimer's disease beta-amyloid production. Biochim Biophys Acta 2010, 1801:860-867.
154. Wada S., Morishima-Kawashima M., Qi Y., Misono H., Shimada Y., Ohno-Iwashita Y., Ihara Y. Gamma-secretase activity is present in rafts but is not cholesterol-dependent. Biochemistry 2003, 42(47):13977-13986.
155. Wallin A.K., Blennow K., Zetterberg H., Londos E., Minthon L., Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 2010, 74:1531-1537.
156. Wang L., Chiang H.C., Wu W., Liang B., Xie Z., Yao X., Ma W., Du S., Zhong Y. Epidermal growth factor receptor is a preferred target for treating amyloid-β-induced memory loss. Proc Natl Acad Sci U S A 2012, 109(41):16743-16748.
157. Wilhelmus M.M.M. Apolipoprotein e and LRP1 increase early in Parkinson's disease pathogenesis. Am J Pathol 2011, 179(5):2152-2156.
158. Williams T.L., Serpell L.C. Membrane and surface interactions of Alzheimer's Aβ peptide-insights into the mechanism of cytotoxicity. FEBS J 2011, 278(20):3905-3917.
159. Williamson R., Usardi A., Hanger D.P., Anderton B.H. Membrane-boundbeta-amyloidoligomers are recruited into lipid rafts by a fyn-dependent mechanism. FASEB J 2008, 22(5):1552-1559.
160. Won J.S., Im Y.B., Kim J., Singh A.K., Singh I. Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesis. Biochem Biophys Res Commun 2010, 399(4):487-491.
161. Wood W.G., Schroeder F., Igbavboa U., Avdulov N.A., Chochina S.V. Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiol Aging 2002, 23(5):685-694.
162. Wu Y., Le W., Jankovic J. Preclinical biomarkers of Parkinson disease. Arch Neurol 2011, 68(1):22-30.
163. Wymo A., Prince M. World Alzheimer report 2010. The global economic impact of Dementia 2010, Alzheimer's Disease International, http://www.alz.org/documents/national/World_Alzheimer_Report_2010.pdf.
164. Yakunin E., Moser A., Loeb V., Saada A., Faust P., Crane D.I., Baes M., Sharon R. Alpha-synuclein abnormalities in mouse models of peroxisome biogenesis disorders. J Neurosci Res 2010, 88(4):866-876.
165. Yao J.K., Wengenack T.M., Curran G.L., Poduslo J.F. Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice. Neurochem Res 2009, 34(1):102-108.
166. Young G., Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev 2005, 45(1):1-28.
167. Yoon I.S., Chen E., Busse T., Repetto E., Lakshmana M.K., Koo E.H., Kang D.E. Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway. FASEB J 2007, 21(11):2742-2752.
168. Zha Q., Ruan Y., Hartmann T., Beyreuther K., Zhang D. GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol Psychiatry 2004, 9(10):946-952.
169. Zetterberg H., Blennow K. Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?. J Alzheimers Dis 2012, 33(Suppl. 1):S361-S369.
170. Zhu M., Fink A.L. Lipid binding inhibits alpha-synuclein fibril formation. J Biol Chem 2003, 278:16873-16877.